Fennec resubmits NDA to FDA for PEDMARK to prevent pediatric ototoxicity

FENNEC PHARMACEUTICALS INC.

Resubmitted New Drug Application (NDA) for PEDMARK (sodium thiosulfate anhydrous injection).
Indication: prevent platinum-induced ototoxicity in pediatric patients (1 month to <18 years) with localized solid tumors.
CEO Rosty Raykov cited close work with FDA during the review process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.